Presented by Martin G. Sanda, MD, University of Michigan, Ann Arbor.
Patents expand production of Gallium-68 for prostate cancer
The patents apply exclusively to the Ga-68 HBED-PSMA-11 production kit (Locametz), developed by Advance Accelerator Applications.
How APPs can bridge the gap in urologist shortages
In this episode, Janelle Bunce, PA-C, highlights the role that advanced practice providers can play in filling the gaps created by the growing workforce shortages in urology.
Midlantic Urology’s Dr. Dean Laganosky is first US urologist to implant FDA-approved balloon spacer for prostate cancer
“This next-generation rectal spacing option is the first of its kind...and has the potential to provide an enhanced degree of protection from the genitourinary and rectal effects of prostate cancer radiation therapy,” said Dr. Laganosky.
Dr. Schuster highlights the FDA approval of imaging agent flotufolastat F 18 in prostate cancer
"We're excited that the FDA approval of this radiotracer gives us yet more tools at our disposal to diagnose prostate cancer in all its forms, from early to late in the disease process," says David M. Schuster, MD, FACR.
FDA grants cretostimogene grenadenorepvec Breakthrough and Fast Track Designations for NMIBC
The designations, which will expedite the development and regulatory review of cretostimogene grenadenorepvec in this setting, are supported by results from the phase 3 BOND-003 trial.
FDA grants priority review to frontline nivolumab-based regimen for urothelial carcinoma
The application is based on results from the phase 3 CheckMate-901 trial.
2 Clarke Drive Cranbury, NJ 08512